Haptoglobin Administration for Intravascular Hemolysis: A Systematic Review
Blood Purification · 05.08.2024 · 1-9
DOI: 10.1159/000539363 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Blood Purification, online erschienen am 05.08.2024. Verfasst von Luca Baldetti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cardiac Intensive Care Unit, IRCCS "San Raffaele Scientific Institute,", Milan, Italy. Hauptthemen laut MEDLINE: Haptoglobins, Hemolysis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Exogenous haptoglobin administration may enhance plasma-free hemoglobin (pfHb) clearance during hemolysis and reduce its end-organ damage: we systematically reviewed and summarized available evidence on the use of haptoglobin as a treatment for hemolysis of any cause.
Methods
We included studies describing haptoglobin administration as treatment or prevention of hemolysis-related complications. Only studies with a control group reporting at least one of the outcomes of interest were included in the quantitative synthesis. Primary outcome was the change in pfHb concentration 1 h after haptoglobin infusion.
Results
Among 573 articles, 13 studies were included in the review (677 patients, 52.8% received haptoglobin). Median initial haptoglobin intravenous bolus was 4,000 (2,000, 4,000) IU. Haptoglobin was associated with lower pfHb 1 h (SMD −11.28; 95% CI: −15.80 to −6.75; p < 0.001) and 24 h (SMD −2.65; 95% CI: −4.73 to −0.57; p = 0.001) after infusion. There was no difference in all-cause mortality between haptoglobin-treated patients and control group (OR 1.41; 95% CI: 0.49–4.95; p = 0.520). Haptoglobin was associated with a lower incidence of acute kidney injury (OR 0.64; 95% CI: 0.44–0.93; p = 0.020). No adverse events or side effects associated with haptoglobin use were reported.
Conclusions
Haptoglobin administration has been used in patients with hemolysis from any cause to treat or prevent hemolysis-associated adverse events. Haptoglobin may reduce levels of pfHb and preserve kidney function without increase in adverse events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiac Intensive Care Unit, IRCCS "San Raffaele Scientific Institute,", Milan, Italy.
- Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy, labanca.rosa@hsr.it.
- Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Cardiology Department, Centro Hospitalar Universitário de Santo António, Porto, Portugal.
- Department of Intensive Care Medicine, Kameda Medical Center, Kamogawa, Japan.
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Zitieren
APA
Baldetti, L., Labanca, R., Belletti, A., Dias-Frias, A., Peveri, B., Kotani, Y., Fresilli, S., Calvo, F., Fominskiy, E., Pieri, M., Ajello, S., & Scandroglio, A. M. (2024). Haptoglobin Administration for Intravascular Hemolysis: A Systematic Review. Blood Purification, 1-9. https://doi.org/10.1159/000539363
Vancouver
Baldetti L, Labanca R, Belletti A, Dias-Frias A, Peveri B, Kotani Y, et al. Haptoglobin Administration for Intravascular Hemolysis: A Systematic Review. Blood Purification. 2024:1-9. doi:10.1159/000539363
BibTeX
@article{Baldetti2024,
author = {Baldetti, Luca and Labanca, Rosa and Belletti, Alessandro and Dias-Frias, André and Peveri, Beatrice and Kotani, Yuki and Fresilli, Stefano and Calvo, Francesco and Fominskiy, Evgeny and Pieri, Marina and Ajello, Silvia and Scandroglio, Anna Mara},
title = {Haptoglobin Administration for Intravascular Hemolysis: A Systematic Review},
journal = {Blood Purification},
year = {2024},
pages = {1--9},
doi = {10.1159/000539363}
}
EUVIMED